The most recent research report issued by CITIC Construction Investment Securities highlights that the AI-driven pharmaceutical industry chain has established a network-enabled system, centered around platforms and technology middleware. This system is characterized by profound collaboration throughout the upstream, midstream, and downstream sectors, and is witnessing a concurrent evolution of multiple business models. AI4S (AI-powered scientific research) is transitioning from a phase dominated by model capability rivalry to a pivotal juncture of industrialization. Technological advancements, industrial cooperation, market demand, and policy backing are converging to create a quadruple synergy, driving the industry's value proposition from merely showcasing individual model capabilities to enhancing scientific research productivity, amassing data assets, and elevating systematic biological design proficiencies.